BETHESDA, Md.--(BUSINESS WIRE)--Dec. 14, 2005--RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN) (www.regenerx.com) reported that it received notification that the State Intellectual Property Office of the People's Republic of China (CSIPO) has allowed its first patent application for the Company's Thymosin beta 4 (TB4) wound healing technology platform in that country.
